Key facts
- This page summarizes Padmanabh P. Bhatt's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 22 reported transactions and 8 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 17:18.
Padmanabh P. Bhatt - 16 Mar 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Reporting relationship
- Sr. VP of IP, CSO
- Issuer ticker
- SUPN
- Reported as of
- 16 Mar 2026
- Net transaction value
- -$5,388,432
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2026, 17:18:35 UTC
- Prior SEC filing
- 26 Feb 2026
- Next SEC filing
- 31 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Padmanabh P. Bhatt filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 18 Mar 2026.
Change
- Previous filing in this sequence was filed on 26 Feb 2026.
- Current net transaction value: -$5,388,432.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001539215
Primary reporting owner
Bhatt Padmanabh P.
- Relationship
- Sr. VP of IP, CSO
- Address
- C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE
- Signature
- /s/ Timothy C. Dec, as attorney-in-fact
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +22,750
- Change %
- +133%
- Price
- $36.75*
- Shares after
- 39,794
- Date
- 16 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,250
- Change %
- +11%
- Price
- $29.61*
- Shares after
- 44,044
- Date
- 16 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +18,000
- Change %
- +41%
- Price
- $32.20*
- Shares after
- 62,044
- Date
- 16 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,000
- Change %
- +8.1%
- Price
- $27.94*
- Shares after
- 67,044
- Date
- 16 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Sale
- Transaction value
- $1,711,841
- Shares
- -34,114
- Change %
- -51%
- Price
- $50.18
- Shares after
- 32,930
- Date
- 16 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F2
SUPN
transaction
Common Stock
Sale
- Transaction value
- $802,084
- Shares
- -15,886
- Change %
- -48%
- Price
- $50.49
- Shares after
- 17,044
- Date
- 16 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F3
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +22,750
- Change %
- +133%
- Price
- $39.40*
- Shares after
- 39,794
- Date
- 17 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +12,250
- Change %
- +31%
- Price
- $36.75*
- Shares after
- 52,044
- Date
- 17 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +15,000
- Change %
- +29%
- Price
- $38.60*
- Shares after
- 67,044
- Date
- 17 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Sale
- Transaction value
- $1,384,114
- Shares
- -27,710
- Change %
- -41%
- Price
- $49.95
- Shares after
- 39,334
- Date
- 17 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F4
SUPN
transaction
Common Stock
Sale
- Transaction value
- $1,130,772
- Shares
- -22,290
- Change %
- -57%
- Price
- $50.73
- Shares after
- 17,044
- Date
- 17 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F5
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,250
- Change %
- +43%
- Price
- $39.40*
- Shares after
- 24,294
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Sale
- Transaction value
- $338,823
- Shares
- -6,838
- Change %
- -28%
- Price
- $49.55
- Shares after
- 17,456
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F6
SUPN
transaction
Common Stock
Sale
- Transaction value
- $20,798
- Shares
- -412
- Change %
- -2.4%
- Price
- $50.48
- Shares after
- 17,044
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -22,750
- Change %
- -65%
- Price
- $0.000000*
- Shares after
- 12,250
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,750
- Exercise price
- $36.75
- Footnotes
- F1, F7
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -4,250
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,250
- Exercise price
- $29.61
- Footnotes
- F1, F8
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -18,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,000
- Exercise price
- $32.20
- Footnotes
- F1, F9
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -5,000
- Change %
- -25%
- Price
- $0.000000*
- Shares after
- 15,000
- Date
- 16 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $27.94
- Footnotes
- F1, F10
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -22,750
- Change %
- -76%
- Price
- $0.000000*
- Shares after
- 7,250
- Date
- 17 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,750
- Exercise price
- $39.40
- Footnotes
- F1, F11
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -12,250
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 17 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,250
- Exercise price
- $36.75
- Footnotes
- F1, F7
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -15,000
- Change %
- -75%
- Price
- $0.000000*
- Shares after
- 5,000
- Date
- 17 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $38.60
- Footnotes
- F1, F12
SUPN
transaction
Derivative
Employee Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -7,250
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,250
- Exercise price
- $39.40
- Footnotes
- F1, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 12 footnotes
Footnote F1
Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.34 to $50.34. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.77. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $50.39. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.40 to $51.15. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $49.99. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Footnote F7
The option vested in four equal annual installments beginning on February 22, 2020.
Footnote F8
The option vested in four equal annual installments beginning on February 19, 2022.
Footnote F9
The option vests in four equal annual installments beginning on February 22, 2023.
Footnote F10
The option vests in four equal annual installments beginning on February 22, 2025.
Footnote F11
The option vested in four equal annual installments beginning on February 14, 2019.
Footnote F12
The option vests in four equal annual installments beginning on February 23, 2024.